Table 1.
Participant characteristics
| USC discovery cohort (n = 68) |
ADNI replication cohort (n = 138) |
|||||
|---|---|---|---|---|---|---|
| CN (n = 19) | MCI-risk (n = 43) | MCI (n = 6) | CN (n = 73) | MCI (n = 45) | AD (n = 20) | |
| Age (years)c | 62.7 ± 9.1 | 66.6 ± 6.9 | 68.7 ± 5.5 | 72.7 ± 6.6 | 74.3 ± 7.5 | 76.6 ± 7.3 |
| Sexc | 16 F (84%) | 30 (70%) | 4 F (67%) | 39 F (53%) | 18 (40%) | 6 (29%) |
| Global GM CBFc | 40.4 ± 6.4 | 41.0 ± 8.6 | 40.1 ± 14 | 48.3 ± 11 | 43.5 ± 11 | 40.7 ± 16a |
| Education (years) | 16.9 ± 1.6 | 16.9 ± 2.5 | 15.5 ± 2.5 | 16.8 ± 2.4 | 16.6 ± 2.7 | 16.0 ± 2.6 |
| APOE4 carrier* | 11 (61%) | 11 (26%)a | 4 (67%)b | 24 (34%) | 11 (27%) | 8 (44%) |
| MoCA | 28.3 ± 1.5 | 26.5 ± 2.5a | 20.3 ± 4.2a,b | 25.8 ± 2.6 | 23.2 ± 3.2a | 17.8 ± 4.4a,b |
| Amyloid (CLs) | 13.1 ± 15 | 17.1 ± 26 | 59.6 ± 44 | 20.9 ± 30 | 31.9 ± 44 | 89.7 ± 35a,b |
| Braak stage 1/2 FTP SUVR | 1.15 ± 0.1 | 1.19 ± 0.1 | 1.54 ± 0.3a,b | 1.19 ± 0.1 | 1.22 ± 0.2 | 1.40 ± 0.2 |
| Braak stage 3/4 FTP SUVR | 1.13 ± 0.1 | 1.13 ± 0.1 | 1.52 ± 0.4a,b | 1.13 ± 0.1 | 1.19 ± 0.2 | 1.50 ± 0.3a,b |
| Injected dose – FTP (mCi)c | 10.5 ± 0.4 | 10.6 ± 1.5 | 10.4 ± 0.6 | 10.1 ± 0.8 | 10.2 ± 0.5 | 10.4 ± 0.3a,b |
F, Female.
aSignificantly different from CN group within cohort, p < 0.05.
bSignificantly different from MCI-risk (USC) or MCI (ADNI) group within cohort, p < 0.05.
cSignificant difference between USC and ADNI cohort, p < 0.05.
*Data unavailable for 10 participants.